Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.07% |
| Dec 31, 2025 | -16.19% |
| Sep 30, 2025 | 39.54% |
| Jun 30, 2025 | 5.53% |
| Mar 31, 2025 | -27.15% |
| Dec 31, 2024 | 23.36% |
| Sep 30, 2024 | 17.23% |
| Jun 30, 2024 | 3.13% |
| Mar 31, 2024 | 18.89% |
| Dec 31, 2023 | 50.36% |
| Sep 30, 2023 | 9.54% |
| Jun 30, 2023 | 73.17% |
| Mar 31, 2023 | -10.94% |
| Dec 31, 2022 | 66.29% |
| Sep 30, 2022 | 48.85% |
| Jun 30, 2022 | 23.34% |
| Mar 31, 2022 | 16.60% |
| Dec 31, 2021 | -16.09% |
| Dec 31, 2020 | 64.45% |
| Dec 31, 2019 | 26.88% |